Associated Papers
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
38564707 (PubMed )
Supplement: cd-23-1217_supplementary_table_5_suppst5.xlsx › table_uff
Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations.
Inoue S et al.
Nature Communications, 2019
31857578 (PubMed )
Supplement: 41467_2019_13708_MOESM12_ESM.xlsx › SD9_SNV_VT
Select a paper to view details